4.7 Article

Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation

Journal

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 77, Issue 5, Pages 1379-1384

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkac021

Keywords

-

Funding

  1. Foundation for Assistance to Small Innovative Enterprises, Russia [16215GU/2021]

Ask authors/readers for more resources

This study aimed to describe the pharmacokinetics of polymyxin B in patients receiving veno-venous extracorporeal membrane oxygenation (ECMO) compared to critically ill patients without ECMO support. The results showed that the currently recommended dosage of polymyxin B is sufficient for ECMO patients and no dosage increase is required.
Objectives To describe polymyxin B pharmacokinetics in patients receiving veno-venous extracorporeal membrane oxygenation (ECMO) in comparison with critically ill patients without ECMO support and to explore potential covariates that could affect the pharmacokinetics in this group of patients. Patients and methods In 13 critically ill patients on ECMO and in 21 critically ill patients without ECMO support, 6-8 blood samples were collected during 12 h intervals after reaching steady state. Polymyxin B concentration in serum was determined using a previously developed ELISA. Protein binding was assessed by rapid equilibrium dialysis. Results In 13 critically ill patients on ECMO who received polymyxin B, the median area under the concentration-time curve over 12 h (AUC(0-12h)) was 48.38 mg/h/L for the total drug and 14.08 mg/h/L for the free drug. The unbound fraction was 0.35. Total body clearance was 1.16 L/h. In non-ECMO patients, the median AUC(0-12h) was 34.7 mg/h/L and the median CL was 1.76 L/h. The volume of distribution was significantly lower in ECMO patients (19.7 versus 30.4 L, respectively). We found a moderate negative correlation between the ECMO blood flow rate and AUC(0-12h), a strong negative correlation between SOFA score and polymyxin B clearance and a moderate correlation between polymyxin B clearance and renal function in ECMO patients. Conclusions Currently recommended polymyxin B dosage regimens are sufficient for patients receiving ECMO and no dosage increase is required. In our study, polymyxin B exposure was higher in ECMO patients compared with the control group.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available